RxDoctor Payments Data

Trixy Headden, NP

Gerontology · Roanoke, VANPI 1023502911

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 30.8% of the total. Reporting peaked in 2024 at $356 and has fallen 93.9% since, to $22 in 2025.

$457in general payments, 2019–2025

Across 16 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$141
  • Johnson & Johnson$55
  • Pfizer$49
  • Irhythm Technologies, Inc.$36
  • Acadia Pharmaceuticals Inc$33
  • Merck$32
  • plus $111 from 7 others

What the payments were for

  • Food & beverage$457100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$457 in reported general payments places this provider in the 55th percentile of 130 gerontology providers in Virginia.

See all gerontology providers in Virginia

Medicare billing

Part B allowed, 2024
$20,341
Medicare patients
55
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$21,757
XareltoRivaroxaban25$15,820
CreonLipase/Protease/Amylase22$10,333
ArexvyRsvpref3 Antigen/As01e/Pf19$5,960
AbrysvoRsv Vacc, Pref A And Pref B/Pf14$4,412
AptiomEslicarbazepine Acetate11$3,986
Atorvastatin Calcium98$3,788
Lacosamide15$3,025
Levetiracetam31$1,563
Famotidine38$1,324
Amlodipine Besylate92$1,298
Ranolazine ErRanolazine20$1,291
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$1,227
Potassium Chloride50$1,223
Gabapentin42$1,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$49$26,16959 claims
Johnson & JohnsonXarelto$55$15,82025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 130 gerontology providers in Virginia.

Other gerontology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →